Citations

Clear

16280 citation(s) found for "Yu, David".

Abstract P2098: The Interaction of Vascular Risk Factors in Midlife and Late-life on Incident Dementia: The Atherosclerosis Risk in Communities Neurocognitive Study
Gottesman, Rebecca F., Palta, Priya , Windham, B. Gwen , Coresh, Josef, Sharrett, A. Richey , Gross, Alden L. , Smith, Jason A. , Pike, James Russell , Lutsey, Pamela L. , Selvin, Elizabeth , Knopman, David S. , Deal, Jennifer A.

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p2098 Get It

Introduction: Vascular risk factors of hypertension, diabetes, and smoking in midlife (45-64 years) and possibly early late-life (65-74 years) are associated with increased risk of dementia. Current estimates of population attributable risk for dementia assume vascular factors are independent and do not interact to increase risk of dementia, which may underestimate the combined impact of vascular risk reduction on dementia incidence. In this study, we evaluated the joint association and interaction of vascular risk factors on risk of dementia. Methods: We performed a prospective cohort analysis using the Atherosclerosis Risk in Communities Neurocognitive Study using up to 33 years of follow-up (1987-2020). We used age as baseline (45-54 years, n=7,731; 55-64 years, n=12,273; and 65-74 years, n=6,660). We defined hypertension as systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥80 mm Hg, or anti-hypertension medication use. We defined diabetes as fasting glucose level ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, self-reported physician diagnosis, or use of any diabetes medication. Current smoking was self-reported. We investigated additive and multiplicative interactions for combinations of vascular risk factors on incident (adjudicated) dementia by age 80 using joint effect variables in Cox regression models stratified by age of risk factor measurement (45-54 years, 55-64 years, or 65-74 years). For interaction analyses, parameter values >1 indicate positive interaction (synergy) and values <1 indicate negative interaction (antagonism). Results: In participants with risk factors measured in these baseline age strata, there were 801 (10%), 995 (8%), and 422 (6%) cases of incident dementia by age 80, respectively. Hypertension and diabetes exhibited positive interactions on the additive and multiplicative scales in midlife (Figure 1). Diabetes and smoking in midlife had positive additive interaction (value >1, Figure 2). All vascular risk factor combinations in late-life had negative interactions on the multiplicative scale (values <1, Figures 1-3). Conclusions: Hypertension with diabetes and diabetes with smoking, all measured in midlife, interact to increase risk of dementia by age 80. The overall impact of reducing midlife vascular risk factors on incident dementia could be sizeable. These findings highlight the importance of multifactor interventions addressing combinations of vascular risk factors for dementia prevention strategies.
External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy
Stassen, Robert C , Maas, Carolien C. H. M. , Leong, Stanley P. L. , Kashani–Sabet, Mohammed , White, Richard L. , Pockaj, Barbara A. , Schneebaum, Schlomo , Vetto, John T. , Avisar, Eli , Howard, John H. , O’Donoghue, Cristina, Akkooi, Alexander C. J. van , Grünhagen, Dirk J. , Verhoef, Cornelis , Grünhagen, Dirk J , Olofsson Bagge, Roger , Zager, Jonathan S. , Kosiorek, Heidi , Verhoef, Cornelis , Klaveren, David V. , Bagge, Roger Olofsson

Mayo Clinic

British Journal of Surgery | April 17, 2025 | Volume: 112 | Issue: 4 | Pages: No page available

10.1093/bjs/znaf037 | PMID 40243383 Get It

Abstract Background Recently, a model to predict 5-year recurrence-free survival (RFS) and melanoma-specific survival (MSS) after sentinel lymph node biopsy (SLNB) was published. The aim of this study was to validate that model in a large independent international cohort. Methods The database of the Sentinel Lymph Node Working Group (SLNWG) was analysed for patients with malignant melanoma who underwent SLNB. Patients with clinical stage III melanoma, a history of other malignancies, or receiving concomitant systemic therapies during follow-up were excluded. The model’s predictive performance was evaluated using discrimination and calibration metrics in the eligible cohort. Decision curve analysis was performed to assess the clinical value of the model. Results The external validation cohort consisted of 6174 patients of the SLNWG from the USA, Europe, and Israel. A positive sentinel node was found in 788 patients (12.8%). The area under the time-dependent receiver operating characteristic (ROC) curve of the external validation was 0.76 (95% c.i. 0.74 to 0.77) for RFS and 0.79 (95% c.i. 0.76 to 0.81) for MSS. The model was well calibrated, as the observed 5-year survival rates aligned closely with the predicted survival rates (calibration slope of 0.98 for RFS and calibration slope of 0.99 for MSS). The model provided a net benefit versus the ‘treat all’ and ‘treat none’ strategies at the predetermined probability threshold for recurrence of 45%. Conclusion The model demonstrated good performance in a large heterogeneous independent cohort, emphasizing its robustness. Decision curve analysis revealed a clear net benefit of the model over a treat all strategy, highlighting its potential for clinical use.
Abstract P1062: Pre-Pandemic Thrombo-inflammatory Biomarkers and Risk of Severe Covid-19: the Collaborative Cohort of Cohorts for Covid-19 Research (C4R)
Cushman, Mary , Choi, Yuni , Reiner, Alex P. , Mukaz, Debora Kamin , Xanthakis, Vanessa, Johnson, Andrew D. , Umans, Jason G. , Kandula, Namratha R. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Jacobs, David R. , Demmer, Ryan T. , Tracy, Russell P. , Olson, Nels C. , Doyle, Margaret F. , Raffield, Laura M. , Min, Yuan‐I , Vasan, Ramachandran S. , Xanthakis, Vanessa , Make, Barry J. , Regan, Elizabeth Anne , Bowler, Russell P. , Thyagarajan, Bharat

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1062 Get It

Background: Thrombo-inflammation is a hallmark of acute Covid-19, with higher thrombo-inflammatory markers during infection associated with adverse outcomes. We hypothesized that higher pre-pandemic biomarkers, reflecting a higher thrombo-inflammatory setpoint, might identify people at greater risk of severe manifestations of Covid-19. Hypothesis: Pre-pandemic inflammation markers are associated with risk of hospitalized or fatal (hereafter, “severe”) Covid-19 in a multi-ethnic US sample. Methods: From 2020-2023, C4R harmonized pre-pandemic measures and ascertained Covid-19 across 14 longstanding cohort studies. In 12 cohorts, we assessed biomarker data and covariates from the study visit closest to the pandemic for 6 analytes shown in the Table. HRs of severe Covid-19 by pre-pandemic biomarkers were estimated using cause-specific Cox regression, treating non-severe Covid-19 as a competing risk, and adjusting for pre-pandemic sociodemographic and clinical characteristics. Results: Biomarkers were measured a mean of 20 years before the pandemic with different sample sizes for each (Table footnote). Mean age at the start of the pandemic was in the 60s or 70s depending on the biomarker. The most represented race or ethnic groups were White and Black. The largest sample was for C-reactive protein, and there were 1,001 severe Covid-19 cases among 38,784 participants. In the adjusted models, considered individually, higher CRP, leukocyte count, factor VIII and fibrinogen, but not other markers, were associated with greater risk of severe Covid-19 (Table).Associations were robust across subgroups and time since biomarker measurement (example for C-reactive protein in Figure). Conclusions: In this prospective multi-study analysis of a multi-ethnic population, higher basal levels of thrombo-inflammation markers were associated with greater risk of severe Covid-19. Since we considered non-severe Covid-19 as a competing risk, associations may reflect factors related to progression to more serious Covid-19 illness.
The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence
Planche, Vincent , Knopman, David S., Frisoni, Giovanni B. , Schneider, Lon S. , Karlawish, Jason , Villain, Nicolas , Schindler, Suzanne E. , Galasko, Douglas , Grill, Joshua D.

Mayo Clinic

Alzheimer's & Dementia | April 17, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70068 | PMID 40243238 Get It

Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study
Balte, Pallavi , Sun, Yifei , Allen, Nori, Arynchyn, Alexander , Bowler, Russell P. , Elkind, Mitchell S, Garcia‐Bedoya, Olga , Garudadri, Suresh , Hansel, Nadia N. , Hermann, E.A. , Hoffman, Eric A. , Kaplan, Robert C. , Laine, Andrew F. , Lynch, David A. , Matsushita, Kunihiro , McKleroy, William , Naik, Sneha N. , O'Driscoll, O., Rusk, A.M., Salvatore, Mary , Smith, Benjamin M. , Sotres‐Alvarez, Daniela , Umans, Jason G. , Washko, George R. , Woodruff, Prescott G. , Ortega, Victor E. , Oelsner, Elizabeth C. , Balte, Pallavi P , Bowler, Russell P , San Jose Estepar, Raul , Hoffman, Eric A , Humphries, Stephen M , Krishnan, Jerry A , Podolanczuk, Anna J , Rusk, Annie, Wenzel, Sally E , Oelsner, Elizabeth C , Kim, John S. , Allen, Nori, Angelini, Elsa D. , Barr, R. Graham , Blaha, Michael Joseph , Carr, J. Jeffrey , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Doyle, Margaret F. , Estépar, Raúl San Jośe , Humphries, Stephen M. , Hunninghake, Gary M. , Lee, Joyce , Make, Barry J. , Min, Yuan‐I , O’Connor, George T. , Oren, Eyal , Podolanczuk, Anna J. , Post, Wendy S. , Pottinger, Tess D. , Regan, Elizabeth Anne , Schwartz, David A. , Vasan, Ramachandran S. , Wenzel, Sally E. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2025 | Volume: 211 | Issue: 7 | Pages: 1196-1210

10.1164/rccm.202408-1656oc | PMID 40238945 Get It

Abstract Rationale Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. Objectives To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Methods Prepandemic obstruction (FEV1/FVC &lt; 0.70) and restriction (FEV1/FVC ⩾ 0.7, FVC &lt; 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population–based cohorts. Severe obstruction was classified by FEV1 &lt; 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Measurements and Main Results Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02–1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12–1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03–2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Conclusions Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.
Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis
Sun, Bo , Fernandes, Dominique , Soltys, John , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Fichtner, Miriam L. , Donat, Robert F. , Akdeniz, Deniz, Bayuangga, Halwan Fuad , Im, Min Gyu , Williams, Robyn , VASCONCELOS, ANA RAQUEL GOUVEIA , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Davies, Alexander J. , Tseng, Mandy , Handel, Adam E. , Kelly, Mark , Zhao, Meng , Bancroft, James , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Dustin, Lynn B. , Rinaldi, Simon , Owens, Raymond J. , Anthony, Daniel C. , Bennett, David , Davis, Simon J. , Wilson, Michael R. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa , Irani, Sarosh R. , Kienzler, Anne-Kathrin , Paneva, Sofija , Harrison, Ruby , Harrison, Anna L , Fichtner, Miriam L , Bayuangga, Halwan , Im, Min Gyu , Vasconcelos, Ana , Fower, Andrew , Fox, Hannah , Davies, Alexander , Tseng, Mandy , Handel, Adam , Kelly, Mark , Zhao, Meng , Bancroft, James , Pluvinage, John V , Dandekar, Ravi , Alvarenga, Bonny D , Dustin, Lynn B , Rinaldi, Simon , Owens, Ray , Anthony, Daniel , Bennett, David L , Davis, Simon J , Wilson, Michael R , O'Connor, Kevin C , Carvalho, Ana Luisa , Irani, Sarosh R , Sun, Bo , Williams, Robyn L , Ramanathan, Sudarshini , Sun, Ruyue, Waters, Patrick

Mayo Clinic

Science Advances | April 16, 2025 | Volume: 11 | Issue: 16 | Pages: No page available

10.1126/sciadv.adr9986 | PMID 40238887 Get It

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Block, Matthew S. , Nelson, Garth D. , Chen, Jun , Johnson, Stephen , Yang, Lu , Flotte, Thomas J. , Grewal, Eric P. , McWilliams, Robert R. , Kottschade, Lisa A. , Domingo‐Musibay, Evidio , Montane, Heather N. , Hui, Jane Yuet Ching , Erskine, Courtney L. , Zahrieh, David , Flotte, Thomas James , Markovic, Svetomir , Dimou, Anastasios , Montane, Heather N , Piltin, Mara , Price, Daniel L , Khariwala, Samir S , Hui, Jane Yuet Ching , Erskine, Courtney L , Strand, Carrie A , Zahrieh, David , Dong, Haidong , Hieken, Tina J , McWilliams, Robert R , Chen, Jun , Grewal, Eric P , Johnson, Stephen , Markovic, Svetomir N. , Dimou, Anastasios , Piltin, Mara A. , Price, Daniel L. , Strand, Carrie , Dong, Haidong , Hieken, Tina J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 15, 2025 | Volume: 13 | Issue: 4 | Pages: e011706

10.1136/jitc-2025-011706 | PMID 40234093 Get It

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083.
Mini-invasive Anterior Petrosal Intertentorial Approach for Trigeminal Neuralgia: Rationale and Limits of the Technique
Giammattei, Lorenzo , Peters, David R. , Mellal, Amine , Starnoni, Daniele, Daniel, Roy Thomas , Peters, D , Squair, Jordan W. , Fava, Arianna , Aureli, Viviana , Pistocchi, Silvia

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | April 15, 2025 | Volume: 87 | Issue: 02 | Pages: 144-150

10.1055/a-2587-6267 | PMID 41808976 Get It

Abstract The retrosigmoid approach (RSA) is considered the standard surgical choice to address a neurovascular conflict involving the trigeminal nerve. The subtemporal transtentorial approach (STA) represents the main alternative. We describe here the mini-invasive anterior petrosal intertentorial approach with a view to reduce complications associated with the standard STA. Mini-invasive anterior petrosal intertentorial approach (M-APIA) was described for a case of refractory trigeminal neuralgia. This approach includes a very limited amount of drilling of the petrous ridge to expose the posterior fossa dura and the superior petrosal sinus to facilitate the subsequent tentorial peeling. Tentorial peeling enables to develop an intertentorial plane between the temporal tentorial leaf (TTL) and the posterior fossa tentorial leaf (PFTL). A linear incision over the posterior fossa dura and the PFTL offers a wide exposure of the neurovascular conflict. M-APIA enables to expose the root entry zone (REZ) of the trigeminal nerve without exposing the temporal lobe or the cerebellum. M-APIA can be considered as a safe alternative to the RSA or STA for trigeminal microvascular decompression (MVD), especially for select cases. Additional studies are needed for a better understanding of its advantages and disadvantages.
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
Puttkammer, Jenna R. , Barreto, Jason N. , Jensen, Chelsee , Nedved, Adrienne, Wilson-Miller, Justine L., Cole, Kristin C., Holmes, Lucy , Kosobud, A., Kapoor, Prashant , Gertz, Morie A. , Dingli, David , Kumar, Shaji , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Binder, Moritz , Sandahl, Tyler B. , Mara, Kristin C. , Jensen, Chelsee J , Nedved, Adrienne N , Holmes, Lucy M, Kosobud, Allison R, Gonsalves, Wilson , Kumar, Shaji K , Kourelis, Taxiarchis V, Warsame, Rahma , Binder, Moritz , Cook, Joselle M , Lin, Yi , Sandahl, Tyler B , Gertz, Morie A , Dingli, David , Mara, Kristin C , Holmes, Lucy M., Kosobud, Allison R., Gonsalves, Wilson I. , Cook, Joselle , Lin, Yi

Mayo Clinic

JCO Oncology Practice | April 15, 2025 | Volume: 22 | Issue: 1 | Pages: 83-90

10.1200/op-24-00930 | PMID 40233295 Get It

PURPOSE Cytokine release syndrome (CRS) of any grade occurs in 56%-80% of bispecific antibodies (BsAbs) used in multiple myeloma (MM). Risk mitigation strategies are required to expedite escalation of care if toxicities develop. The rarity of grade 3 or 4 CRS compels protocolized outpatient management of BsAbs as outpatient practice may avoid hospital admissions and costly resource utilization without compromising safety. MATERIALS AND METHODS Patients with MM who received BsAb step-up dosing (SUD) from August 23, 2023, to March 29, 2024, were enrolled. Baseline demographics, patient outcomes, and CRS management were reviewed to assess the safety of outpatient practice. Resource utilization was also analyzed. RESULTS In this study, 34 patients received outpatient SUD of BsAbs (teclistamab n = 17, talequetamab n = 17) with 16 remaining outpatient throughout the entire SUD period. CRS occurred in seven patients who did not require hospitalization, demonstrating the safety of outpatient management of BsAb toxicity, regardless of low-grade CRS. CRS was observed in 24 patients (maximum grade 2) and immune effector cell–associated neurotoxicity syndrome in four patients (maximum grade 3). All patients with CRS received steroids, including 12 patients at home when instructed. Tocilizumab was given to 13 patients, accounting for 18 doses. If all doses of BsAbs and tocilizumab were given outpatient, the medication margin would be $115,004 in US dollars (USD). CONCLUSION An outpatient-based practice for BsAb administration demonstrated safety and cost savings. The description of our practice and results of this study provide valuable insights into the safety, feasibility, and resource stewardship of outpatient management of BsAbs. Future research should attempt to predict and stratify CRS risk to deliver a tailored supportive strategy and continued increase of outpatient management.
Surgical Recurrence Across Endoscopic Surgical Techniques in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , Ali, Hawa M. , McCalla, Monet, Roitman, Ariel , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Dailey, Seth H. , Ekbom, Dale C. , Bowen, Andrew Jay , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Dailey, Seth H , Ekbom, Dale , Awadallah, Andrew , Bayan, Semirra L. , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | April 15, 2025 | Volume: 135 | Issue: 9 | Pages: 3280-3286

10.1002/lary.32181 | PMID 40231755 Get It

ABSTRACTObjectiveWhile endoscopic laser wedge excision (LWE) for iSGS demonstrated lower surgical recurrence rates compared to endoscopic dilation (ED), ED remains the primary technique employed. Additionally, serial intralesional steroid injections (SILSIs) also demonstrate benefits in controlling disease. We aimed to compare surgical recurrence rates following ED, ED + SILSI, and LWE following a patient's first operation.MethodsThis was a two‐center retrospective analysis of iSGS patients who underwent either ED, ED + SILSI, or LWE. Patients were followed to their last follow‐up date or reoperation. Kaplan–Meier analysis and Cox proportional hazards were used to evaluate the recurrence times across the different surgical groups with additional stratification by age, compliance to medical adjuvant therapy, and percentage of stenosis rated at reoperation.ResultsA total of 126 patients from Institution 1 underwent LWE, while at Institution 2, ED and ED + SILSI were performed on 32 and 23 patients, respectively. One‐year recurrence estimates were 9%, 53%, and 0% for LWE, ED, and ED + SILSI, respectively, while 5‐year recurrence estimates were 45%, 90%, and 19%, respectively. Adjusted Cox‐proportional hazard ratios demonstrated a greater risk of surgical recurrence with ED compared to LWE (2.25; 95% confidence interval [CI]: 1.31–3.88) and no difference between ED + SILSI and LWE (0.84; 95% CI: 0.32–2.25).ConclusionLWE demonstrates reduced recurrence times compared to ED when controlling for surgery number, age, triple therapy compliance, and percentage of stenosis at reoperation. The application of postoperative SILSI appears to similarly reduce recurrence rates comparable to LWE and warrants further investigation.